Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 14/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263674 | 0.82 | HRH2 (0.41) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL4830054 | 0.80 | SCN9A (0.49) | HRH2SCN9ASCN5ALMNASMN1; SMN2 | |
| SCHEMBL14435340 | 0.78 | SCN9A (0.45) | HRH2SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL4831650 | 0.78 | HRH2 (0.48) | HRH2SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL772052 | 0.77 | HRH2 (0.44) | HRH2SCN9ASCN5ALMNA | |
| SCHEMBL13577960 | 0.76 | SCN9A (0.46) | HRH2SCN9ASCN5ALMNASMN1; SMN2 | |
| SCHEMBL4822336 | 0.76 | CNR2 (0.47) | HRH2SCN9ASCN5ALMNA | |
| SCHEMBL4827022 | 0.76 | SCN9A (0.46) | HRH2SCN9ASCN5ALMNAMAPT | |
| SCHEMBL1260945 | 0.74 | SCN9A (0.65) | SCN9ASCN5ALMNASMN1; SMN2 | |
| SCHEMBL13577940 | 0.74 | HPGD (0.44) | HRH2SCN9ASCN5ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | HRH2 2383/4885SCN9A 4635/4885SCN5A 4645/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | HRH2 2383/4885SCN9A 4635/4885SCN5A 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.